Biogen (NASDAQ:BIIB) Price Target Increased to $363.00 by Analysts at Royal Bank of Canada
Biogen (NASDAQ:BIIB – Free Report) had its target price lifted by Royal Bank of Canada from $351.00 to $363.00 in a report issued on Thursday, Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock. Other analysts have also recently issued reports about the company. Scotiabank started coverage on Biogen in a […]
More Stories
Thrivent Financial for Lutherans Boosts Holdings in Invesco S&P 500 Top 50 ETF (NYSEARCA:XLG)
Thrivent Financial for Lutherans grew its stake in shares of Invesco S&P 500 Top 50 ETF (NYSEARCA:XLG – Free Report)...
Thrivent Financial for Lutherans Purchases 1,101,796 Shares of iShares U.S. Treasury Bond ETF (BATS:GOVT)
Thrivent Financial for Lutherans boosted its position in iShares U.S. Treasury Bond ETF (BATS:GOVT – Free Report) by 280.3% in...
Swiss National Bank Cuts Stock Holdings in PulteGroup, Inc. (NYSE:PHM)
Swiss National Bank trimmed its holdings in shares of PulteGroup, Inc. (NYSE:PHM – Free Report) by 0.6% in the 3rd...
Swiss National Bank Buys 1,400 Shares of American Water Works Company, Inc. (NYSE:AWK)
Swiss National Bank raised its stake in shares of American Water Works Company, Inc. (NYSE:AWK – Free Report) by 0.2%...
Swiss National Bank Acquires 14,900 Shares of Corning Incorporated (NYSE:GLW)
Swiss National Bank boosted its holdings in shares of Corning Incorporated (NYSE:GLW – Free Report) by 0.6% in the 3rd...
Swiss National Bank Purchases 2,300 Shares of Entergy Co. (NYSE:ETR)
Swiss National Bank grew its position in shares of Entergy Co. (NYSE:ETR – Free Report) by 0.4% during the 3rd...